Brief: Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study Of Mc4r Agonist Bremelanotide And Tirzepatide
17/04/2025 13:43
April 17 (Reuters) - Eli Lilly and Co LLY.N: PALATIN REPORTS POSITIVE APPETITE SUPPRESSION RESULTS FROM PHASE 2 OBESITY STUDY OF MC4R AGONIST BREMELANOTIDE AND TIRZEPATIDE PALATIN TECHNOLOGIES INC - ALL STUDY ARMS SHOWED IMPROVEMENT IN APPETITE SUPPRESSION PALATIN TECHNOLOGIES INC - BREMELANOTIDE MATCHED OR EXCEEDED TIRZEPATIDE IN APPETITE SUPPRESSION PALATIN TECHNOLOGIES INC - LOW-DOSE BREMELANOTIDE PREVENTED APPETITE REBOUND AFTER TIRZEPATIDE CESSATION PALATIN TECHNOLOGIES INC - PHASE 2 TRIAL SHOWED SIGNIFICANT WEIGHT LOSS WITH BREMELANOTIDE AND TIRZEPATIDE PALATIN TECHNOLOGIES INC - IND FILINGS EXPECTED BY END OF Q4 2025 Source text: ID:nPn36ffKFa Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity